Patent Law Reform In Mexico: A Strategic Turning Point, Particularly For The Pharma Sector

In April 2026, Mexico implemented a significant reform of its intellectual property legislation, with the objective to modernise the system, accelerate procedures and provide greater legal certainty to innovators. Eric Enderlin explains what has changed and why the reforms to patent law are especially relevant for pharmaceutical companies. 

On 3 April 2026, the Mexican government officially published amendments to the Federal Law for the Protection of Industrial Property. While the reforms apply to all IP rights holders, they are of particular relevance for pharmaceutical companies, for which issues relating to the duration of patent protection are critical.

The patent law reforms cover five key points: 

1. An overall faster but also more demanding system

The reformed patent law introduces several tools aimed at streamlining procedures in Mexico: 

• defined timeframes for administrative decisions, 
• a limitation on the number of exchanges with examiners, and 
• corrective mechanisms in the event of formal errors.

For example, an applicant may now benefit from a short additional period to correct an irregularity or attempt to recover a lost priority right under certain conditions. 

These developments reduce the risk of irreversible errors but, in return, require greater rigour in the management of deadlines. 

2. A major constraint: Shortened examination timelines

The Mexican administration must now issue a decision on a patent application within one year from the start of substantive examination. 

At the same time, the number of official actions is reduced to two. This means, in practical terms, that applicants will have fewer opportunities to adjust their strategy during prosecution. 

While this change may accelerate the granting of rights, it also requires more robust preparation from the filing stage. 

3. Focus: A key development for pharmaceutical patents

The reform introduces a highly anticipated mechanism in the pharma sector: The possibility of compensating for the loss of effective patent term due to regulatory delays. 

—Why is this measure essential? 

In the pharma sector, a patent cannot be commercially exploited until a marketing authorisation has been obtained. However, these procedures may take several years, thereby reducing the period during which the patent holder can effectively exploit the invention while benefiting from patent exclusivity. 

This issue is well known internationally and has already led to the implementation of compensation mechanisms, such as Supplementary Protection Certificates (SPCs) within the European Union or Patent Term Extensions (PTEs) in the United States. 

—A structured compensation mechanism 

The new Mexican framework allows for an extension of protection, subject to strict conditions: 

• the health authority must determine that an excessive delay occurred in the granting of the marketing authorisation; 
• this authority, and not the patent holder, assesses the duration of the delay; 
• once this determination has been made, it requests the patent office to adjust the duration of protection; 
• the extension takes the form of a supplementary certificate, which becomes effective only after the expiration of the original patent.

—A limited but strategic extension 

The duration of this additional protection is capped at five years, even if the delay exceeds this period. 

This reflects a policy balance: on the one hand, protecting substantial investments in pharmaceutical research; on the other hand, avoiding excessive extensions of monopoly rights. 

This mechanism may represent a major economic lever for pharmaceutical companies, enabling them to extend the period during which they can recoup their investments. 

—A critical point of attention: Payment deadlines 

The granting of this extension is not automatic. Once the decision has been made, the patent holder has a very short period (one month) to pay the applicable fees. No remedial mechanism is available in the event of omission. 

This is a particularly sensitive point: a simple administrative oversight may result in the definitive loss of the benefit of the extension. 

—Alignment with international standards 

With this patent law reform, Mexico is aligning itself with practices in force in other major jurisdictions, including the EU and the US. 

This strengthens the country’s attractiveness for pharmaceutical research investments and facilitates integration into global IP strategies. 

4. Other useful tools for innovators

Beyond the pharma sector, several additional developments should be noted: 

• the introduction of provisional patent applications, allowing applicants to secure a filing date quickly, particularly where publication cannot be postponed; 
• the possibility of correcting certain errors relating to priority; 
• an administrative procedure to claim ownership of a patent without invalidating it.

These tools provide greater flexibility and allow protection strategies to be adapted to various contexts. 

5. A promising but still evolving reform

While the objectives of simplification and acceleration are clearly stated, the practical implementation of certain measures remains to be clarified. 

Some mechanisms, such as the committee responsible for addressing administrative delays relating to pharmaceutical patents, are not yet fully operational. In addition, regulatory adjustments are expected, particularly regarding fees and practical procedures. 

Key takeaways from Mexico’s intellectual property law reform

The 2026 reform marks an important step in the evolution of Mexico’s IP system. 

For the pharma sector, the introduction of a patent term compensation mechanism constitutes a major development, likely to have a direct impact on the valuation of innovations. 

However, this modernisation is accompanied by increased requirements in terms of procedural and deadline management. Therefore, companies have a strong interest in anticipating these changes if they are to fully benefit from them. 

In an environment where every month of protection counts, these new Mexican rules are reshaping the landscape, particularly for pharmaceutical stakeholders. 

Novagraaf’s Chemistry and Life Sciences Department operates at the heart of these issues, anticipating patent term extensions, securing critical procedures and integrating these developments into patent strategies that genuinely create value. To find out more about the reforms and how we can support you to secure protection effectively, speak to your Novagraaf patent attorney or contact our team today.